Get the Stockscreener App
1,043.29
0.60%
-6.31
After Hours:
1045.00
1.71
+0.16%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,043.29, with a volume of 3.10M.
It is down -0.60% in the last 24 hours and up +28.97% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,049.60
Open:
$1045.5
24h Volume:
3.10M
Relative Volume:
0.82
Market Cap:
$987.43B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
51.60
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+2.00%
1M Performance:
+28.97%
6M Performance:
+39.66%
1Y Performance:
+38.48%
1-Day Range:
$1,038.25
$1,057.00
1-Week Range:
$998.30
$1,057.00
52-Week Range:
$623.78
$1,057.00
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,043.29 | 939.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
203.07 | 487.91B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.45 | 411.64B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
124.36 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
94.97 | 235.92B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Evaluating Eli Lilly Shares After 30% Surge Driven by Obesity Drug Pipeline News - Yahoo Finance
Eli Lilly & Co. is opening a Lilly Gateway Labs biotech incubator in Philadelphia - The Daily Gazette
Eli Lilly Enters Uncharted Territory as Market Cap Nears $1T - BioSpace
Is Pfizer's 6.9%-Yielding Dividend Still Safe? - The Motley Fool
A “human” approach to healthcare - Fast Company
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales - Nasdaq
Pfizer exec challenges Novo Nordisk, Eli Lilly after Metsera win - medwatch.com
Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly? - Yahoo Finance
Eli Lilly Expands Innovation Network with Strategic Philadelphia Hub - Ad-hoc-news.de
ABLBio (298380 KS): Funding From Lilly To Strengthen Drug Development Capabilities - Smartkarma
News | Drugmaker Eli Lilly to open shared lab space for fledgling biotech startups in Philadelphia - CoStar
Eli Lilly Startup Incubator Coming To Market West: The Philadelphia Deal Sheet (November 19, 2025) - Bisnow
Owner Lilly Endowment Inc Sells 60,213 ($62.3M) Of Eli Lilly & Co [LLY] - TradingView
Owner Lilly Endowment Inc Files To Sell 310,000 Of Eli Lilly & Co [LLY] - TradingView
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday - inkl
Truist Securities Raises Price Target for Eli Lilly (LLY) to $11 - GuruFocus
Will Eli Lilly Stock (LLY) Split? Rumors Are Swirling. - TipRanks
Lilly to open Gateway Labs site in Philadelphia - Inside INdiana Business
Truist Raises Price Target on Eli Lilly to $1,182 From $1,038, Keeps Buy Rating - MarketScreener
Philadelphia Selected for New Lilly Gateway Labs at Breakthrough Properties – 2300 Market Street - BioBuzz
Celltrion to widen US manufacturing reach with $478M investment at former Lilly plant - Fierce Pharma
Eli Lilly (LLY) Expands Biotech Incubator to Philadelphia - GuruFocus
Eli Lilly on "Stock Split Watch": A Deep Dive into a Pharmaceutical Giant's Future - FinancialContent
Lilly to Open Lilly Gateway Labs Site in Philadelphia - Contract Pharma
EXPLORING THE GLOBAL TRANSFORMATION OF HEALTH CARE WITH ELI LILLY's CEO DAVE RICKS - StreetInsider
T. Rowe Price (NASDAQ: TROW) features Eli Lilly CEO on 'The Angle' health care episode - Stock Titan
Eli Lilly Unusual Options Activity For November 19 - Benzinga
Eli Lilly Stock Gains Momentum on Medicare Deal and Optimistic Outlook - AskTraders.com
Lilly Announces Plans To Open Lilly Gateway Labs Site In Philadelphia - citybiz
Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow Tuc - The Economic Times
Truist Raises Price Target on Eli Lilly to $1,182 From $$1,038, Keeps Buy Rating - MarketScreener
The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company - MSN
Eli Lilly (LLY) Announces New Gateway Labs Site in Philadelphia - GuruFocus
Morning Business Report: Rising homeownership costs, Eli Lilly’s surge, and NVIDIA earnings - 41NBC News
Eli Lilly price soarsForecast today19-11-2025 - Economies.com
Truist Securities raises Eli Lilly stock price target to $1,182 on obesity drug outlook - Investing.com India
Lilly to open new Gateway Labs site in Philadelphia By Investing.com - Investing.com South Africa
Lilly to open new Gateway Labs site in Philadelphia - Investing.com
Breakthrough and Lilly partner on new biotech lab space in Philadelphia - Investing.com
'At the top of our game': Lilly picks Philadelphia as next spot for early-stage biotech lab space - Fierce Biotech
Eli Lilly picks Market Street building for its Philadelphia Gateway Labs innovation hub - The Business Journals
Eli Lilly Gains from Big Earnings, Bullish Inflows - FXEmpire
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. - AOL.com
Eli Lilly, Fluor celebrate veterans - reporter.net
The Zacks Analyst Blog Highlights Microsoft, Amazon.com and Eli Lilly - Nasdaq
Eli Lilly (LLY) Poised to Become First Trillion-Dollar Pharma Co - GuruFocus
Eli Lilly Shares Surge as JPMorgan Raises Price Target to $1,150 - Ad-hoc-news.de
Major Shareholder Sells Millions in Eli Lilly Stock! - TipRanks
Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$10.19 Million in Common Stock - 富途牛牛
Is Eli Lilly and Company stock positioned for secular growth2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com
Top Research Reports for Microsoft, Amazon.com & Eli Lilly - Nasdaq
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):